Heva Health review

Heva Health combines a $149 monthly testosterone program with quarterly labs and mobile blood draws, or $199 with optional gonadorelin, on a three-payment minimum. Its prescription shop also lists NAD⁺ nasal spray at $179, NAD⁺ topical cream at $115, topical GHK-Cu at $120–$140 and PT-141 at $89. These one-time shop items are separate from the TRT bundle and from Concierge Care. The site names pharmacy partners in one place but retains a different network name in older terms, so confirm who fulfills the selected prescription and what refund rules apply.

Heva Health is a functional-medicine telehealth practice offering a testosterone program, an enclomiphene alternative, compounded GLP-1 weight care, labs and a separate Concierge Care membership. Its care team is named: Dr. Caroline Tade, NMD, Kasey Horrell, PA-C, Dr. Daniel Hall, DNP, NP-C, and Kelly Moore, FNP. The public prescription shop lists NAD⁺ nasal spray and topical cream, topical GHK-Cu and PT-141 alongside TRT and other items. Gonadorelin is an optional TRT add-on rather than a standalone peptide price. A separate supplement storefront was also examined, but its current home did not establish an NMN listing or prove that any older supplement was withdrawn.

The testosterone program advertises medication if prescribed, quarterly lab panels, mobile phlebotomy, telehealth visits, messaging and shipping in its $149 monthly base price, with optional gonadorelin adding $50 a month and three monthly payments minimum. That monitoring matters for testosterone therapy. Enclomiphene is separately priced, and the public material does not establish that its lab inclusion matches TRT. Concierge Care is a distinct membership at $349 for the first month and $99 afterward, with medication priced separately and only twelve listed states; a one-time Health Assessment is another purchase. The men's hormone program describes 45-state reach, which cannot be transferred to each shop item. The shop describes provider review rather than automatic refills. Heva's how-it-works page names Strive and Stryker as partners, while older terms mention Bask Pharmacy Network; ask who will dispense the selected product. Shop pages describe pre-fulfillment refunds for clinical unsuitability or timely cancellation, while older terms limit paid membership refunds. Match the policy to the program before paying.

TRT remains $149 a month for the base program, with gonadorelin an optional $50 monthly add-on for a $199 total and three monthly payments minimum. Enclomiphene is listed at $149 a month and Enclomiphene+ at $199; do not assume their included services exactly match TRT. The prescription shop lists NAD⁺ nasal spray 300 mg/mL for $179 and NAD⁺ 10% topical cream for $115, each labeled as a one-time charge with no recurring billing. Topical GHK-Cu varies from $120 to $140 by formula and PT-141 is listed at $89; item quantity and duration are not established. Concierge Care costs $349 the first month and $99 monthly afterward with medication separate, while the Health Assessment is a separate $349 one-time offer. Homepage starting-price language should not be substituted for these product-specific charges. Confirm the selected product, clinician approval, state and first debit before ordering.

Compounded products are not FDA-approved finished drugs; prescription items require a licensed clinician's approval. Heva names Strive and Stryker on its how-it-works page, while older terms retain Bask Pharmacy Network; these are seller disclosures, not independent pharmacy validation or a patient-specific assignment. Testosterone therapy has substantial human evidence in men with diagnosed hypogonadism and requires monitoring of hematocrit, PSA and other risks; it can suppress fertility. Enclomiphene has human data for raising endogenous testosterone while preserving fertility markers, but is not FDA-approved for that indication, and the blended Enclomiphene+ ingredients do not share the same evidence. Gonadorelin is presented here for testicular-atrophy support within TRT; evidence in that role is thinner and it is not a growth-hormone or general-wellness peptide. The current shop's NAD⁺ nasal and topical routes have no controlled human outcome evidence for longevity claims. Oral NR and NMN studies concern raised blood NAD⁺, not proven clinical outcomes, and do not validate these prescription routes. Topical GHK-Cu and the listed PT-141 product need their own route, indication and formulation checks; the shop listing alone establishes no FDA approval or clinical outcome. Individual results vary.